查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1728202

色素沉着障碍治疗市场－全球产业规模、份额、趋势、机会和预测，按适应症、治疗和疗法、最终用户、地区和竞争细分，2020-2030 年预测

Pigmentation Disorders Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented by Indication, by Treatment & Therapies, by End User, By Region and Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 178 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

2024 年全球色素沉着障碍治疗市场价值为 67.8 亿美元，预计到 2030 年将达到 102.5 亿美元，预测期内复合年增长率为 7.13%。色素沉淀障碍包括色素沉淀和色素沉淀过少，会因日晒、遗传、发炎和荷尔蒙变化等因素影响皮肤颜色。这些情况可能会导致明显的美容问题，导致许多人寻求治疗以获得更清晰、更均匀的肤色。随着人们意识的增强和对美学的日益重视，对外用药物、化学换肤、雷射疗法和磨皮等治疗的需求持续增长。人口老化、皮肤病学技术创新以及先进配方和设备的引进进一步推动了市场扩张。此外，以护肤为重点的消费者教育和产品开发的激增（特别是含有对苯二酚和烟酰胺等活性成分的乳霜）对市场的成长轨迹做出了重大贡献。

市场概览
预测期 2026-2030
2024年市场规模 67.8亿美元
2030年市场规模 102.5亿美元
2025-2030 年复合年增长率 7.13%
成长最快的领域 皮肤科诊所
最大的市场 北美洲

关键市场驱动因素

技术进步

主要市场挑战

治疗费用

主要市场趋势

个人化医疗

目录

第 1 章：产品概述

第二章：研究方法

第三章：执行摘要

第四章：顾客之声

第五章：全球色素沉着障碍治疗市场展望

  • 市场规模和预测
    • 按价值
  • 市场占有率和预测
    • 依适应症（色素沉淀、色素沉淀过少）
    • 依治疗及疗法分类（化学换肤、磨皮、雷射换肤、黄褐斑）
    • 按最终使用者（皮肤科诊所、医院）
    • 按地区
    • 按公司分类（2024）
  • 市场地图

第六章：亚太地区色素沉着障碍治疗市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 亚太地区：国家分析
    • 中国
    • 印度
    • 澳洲
    • 日本
    • 韩国

第七章：欧洲色素沉着障碍治疗市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 欧洲：国家分析
    • 法国
    • 德国
    • 西班牙
    • 义大利
    • 英国

第八章：北美色素沉着障碍治疗市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 北美：国家分析
    • 美国
    • 墨西哥
    • 加拿大

第九章：南美色素沉着障碍治疗市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 南美洲：国家分析
    • 巴西
    • 阿根廷
    • 哥伦比亚

第十章：中东和非洲色素沉着障碍治疗市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • MEA：国家分析
    • 南非
    • 沙乌地阿拉伯
    • 阿联酋

第 11 章：市场动态

  • 驱动程式
  • 挑战

第 12 章：市场趋势与发展

  • 最新动态
  • 产品发布
  • 併购

第 13 章：全球色素沉着障碍治疗市场：SWOT 分析

第 14 章：波特五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的力量
  • 顾客的力量
  • 替代产品的威胁

第 15 章： 大环境分析

第 16 章：竞争格局

  • Zerigo Health.
  • Bausch Health Companies Inc.
  • Glenmark Pharmaceuticals Limited
  • Novartis AG
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Bayer AG
  • CLINUVEL PHARMACEUTICALS LTD
  • Strides Pharma Science Limited
  • Astellas Pharma Inc.

第 17 章：策略建议

第18章调查会社について・免责事项

简介目录
Product Code: 16971

The Global Pigmentation Disorders Treatment Market was valued at USD 6.78 Billion in 2024 and is projected to reach USD 10.25 Billion by 2030, growing at a CAGR of 7.13% during the forecast period. Pigmentation disorders, encompassing hyperpigmentation and hypopigmentation, affect skin coloration due to factors such as sun exposure, genetics, inflammation, and hormonal changes. These conditions can result in noticeable cosmetic concerns, leading many individuals to seek treatment for clearer, more even-toned skin. With rising awareness and the increasing emphasis on aesthetics, demand for treatments like topical agents, chemical peels, laser therapies, and dermabrasion continues to grow. Aging populations, technological innovation in dermatology, and the introduction of advanced formulations and devices have further propelled market expansion. Additionally, a surge in skincare-focused consumer education and product development-particularly creams containing active ingredients such as hydroquinone and niacinamide-has significantly contributed to the market's growth trajectory.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 6.78 Billion
Market Size 2030USD 10.25 Billion
CAGR 2025-20307.13%
Fastest Growing SegmentDermatology Clinics
Largest MarketNorth America

Key Market Drivers

Technological Advancements

Rapid advancements in technology have greatly enhanced the effectiveness and precision of pigmentation disorder treatments. Innovations in laser-based therapies, including Q-switched, fractional, and picosecond lasers, have enabled targeted treatment of pigmented lesions with minimal risk of scarring. The adoption of Intense Pulsed Light (IPL) systems has broadened treatment accessibility for conditions such as age spots and sun-induced pigmentation. In addition, fractional radiofrequency (RF) devices that integrate microneedling with RF energy offer effective non-invasive treatment with minimal downtime. The refinement of topical formulations through nanotechnology and enhanced transdermal delivery systems has increased the potency and bioavailability of active ingredients. Cryotherapy tools with improved temperature control, along with the emergence of picosecond lasers capable of ultra-short pulse durations, have expanded therapeutic options, especially for resistant pigmentation conditions. These technological strides have collectively improved clinical outcomes and patient satisfaction across diverse skin types and indications.

Key Market Challenges

Cost of Treatment

The high cost of pigmentation treatment poses a significant challenge for broader market accessibility. Procedures such as laser therapy and combination treatment plans can be expensive, especially when multiple sessions are required for optimal results. Out-of-pocket expenses can be substantial, particularly in regions where pigmentation therapy is classified as elective and not covered by insurance. Beyond procedural fees, patients also bear the costs of consultation, follow-ups, prescription creams, and maintenance therapies. Premium skincare products designed for pigmentation disorders can be financially burdensome, and specialized treatments often involve travel to advanced dermatology centers, further escalating costs. The long-term nature of treatment, requiring consistent care and follow-up, adds to the financial strain, thereby limiting treatment adoption among cost-sensitive populations.

Key Market Trends

Personalized Medicine

The shift toward personalized medicine is transforming the treatment of pigmentation disorders. Tailored therapeutic strategies are now being developed based on individual patient factors such as genetic profile, skin type, lifestyle, and prior treatment responses. Genetic insights have enabled identification of mutations and variations linked to pigmentation irregularities, helping clinicians develop targeted therapies. Pharmacogenomic testing further refines this approach by determining the most effective drug or topical agent based on an individual's genetic makeup. Skin type-specific therapies and the integration of multimodal treatments-such as combining chemical peels with laser resurfacing-are gaining traction. Moreover, advancements in laser technology now permit customization of wavelength and energy settings based on patient-specific needs. Empowering patients with information and involving them in treatment decisions is also a key feature of this trend, contributing to improved adherence and satisfaction.

Key Market Players

  • Zerigo Health
  • Bausch Health Companies Inc.
  • Glenmark Pharmaceuticals Limited
  • Novartis AG
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd
  • Bayer AG
  • CLINUVEL PHARMACEUTICALS LTD
  • Strides Pharma Science Limited
  • Astellas Pharma Inc.

Report Scope:

In this report, the Global Pigmentation Disorders Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Pigmentation Disorders Treatment Market, By Indication:

  • Hyperpigmentation
  • Hypopigmentation

Pigmentation Disorders Treatment Market, By Treatment & Therapies:

  • Chemical Peels
  • Dermabrasion
  • Laser Resurfacing
  • Melasma

Pigmentation Disorders Treatment Market, By End User:

  • Dermatology Clinics
  • Hospitals

Pigmentation Disorders Treatment Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Asia-Pacific
    • China
    • India
    • South Korea
    • Australia
    • Japan
  • Europe
    • Germany
    • France
    • United Kingdom
    • Spain
    • Italy
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Pigmentation Disorders Treatment Market.

Available Customizations:

Global Pigmentation Disorders Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Pigmentation Disorders Treatment Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Indication (Hyperpigmentation, Hypopigmentation)
    • 5.2.2. By Treatment & Therapies (Chemical Peels, Dermabrasion, Laser Resurfacing, Melasma)
    • 5.2.3. By End User (Dermatology Clinics, Hospitals),
    • 5.2.4. By Region
    • 5.2.5. By Company (2024)
  • 5.3. Market Map

6. Asia Pacific Pigmentation Disorders Treatment Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Indication
    • 6.2.2. By Treatment & Therapies
    • 6.2.3. By End User
    • 6.2.4. By Country
  • 6.3. Asia Pacific: Country Analysis
    • 6.3.1. China Pigmentation Disorders Treatment Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Indication
        • 6.3.1.2.2. By Treatment & Therapies
        • 6.3.1.2.3. By End User
    • 6.3.2. India Pigmentation Disorders Treatment Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Indication
        • 6.3.2.2.2. By Treatment & Therapies
        • 6.3.2.2.3. By End User
    • 6.3.3. Australia Pigmentation Disorders Treatment Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Indication
        • 6.3.3.2.2. By Treatment & Therapies
        • 6.3.3.2.3. By End User
    • 6.3.4. Japan Pigmentation Disorders Treatment Market Outlook
      • 6.3.4.1. Market Size & Forecast
        • 6.3.4.1.1. By Value
      • 6.3.4.2. Market Share & Forecast
        • 6.3.4.2.1. By Indication
        • 6.3.4.2.2. By Treatment & Therapies
        • 6.3.4.2.3. By End User
    • 6.3.5. South Korea Pigmentation Disorders Treatment Market Outlook
      • 6.3.5.1. Market Size & Forecast
        • 6.3.5.1.1. By Value
      • 6.3.5.2. Market Share & Forecast
        • 6.3.5.2.1. By Indication
        • 6.3.5.2.2. By Treatment & Therapies
        • 6.3.5.2.3. By End User

7. Europe Pigmentation Disorders Treatment Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Indication
    • 7.2.2. By Treatment & Therapies
    • 7.2.3. By End User
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Pigmentation Disorders Treatment Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Indication
        • 7.3.1.2.2. By Treatment & Therapies
        • 7.3.1.2.3. By End User
    • 7.3.2. Germany Pigmentation Disorders Treatment Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Indication
        • 7.3.2.2.2. By Treatment & Therapies
        • 7.3.2.2.3. By End User
    • 7.3.3. Spain Pigmentation Disorders Treatment Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Indication
        • 7.3.3.2.2. By Treatment & Therapies
        • 7.3.3.2.3. By End User
    • 7.3.4. Italy Pigmentation Disorders Treatment Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Indication
        • 7.3.4.2.2. By Treatment & Therapies
        • 7.3.4.2.3. By End User
    • 7.3.5. United Kingdom Pigmentation Disorders Treatment Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Indication
        • 7.3.5.2.2. By Treatment & Therapies
        • 7.3.5.2.3. By End User

8. North America Pigmentation Disorders Treatment Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Indication
    • 8.2.2. By Treatment & Therapies
    • 8.2.3. By End User
    • 8.2.4. By Country
  • 8.3. North America: Country Analysis
    • 8.3.1. United States Pigmentation Disorders Treatment Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Indication
        • 8.3.1.2.2. By Treatment & Therapies
        • 8.3.1.2.3. By End User
    • 8.3.2. Mexico Pigmentation Disorders Treatment Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Indication
        • 8.3.2.2.2. By Treatment & Therapies
        • 8.3.2.2.3. By End User
    • 8.3.3. Canada Pigmentation Disorders Treatment Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Indication
        • 8.3.3.2.2. By Treatment & Therapies
        • 8.3.3.2.3. By End User

9. South America Pigmentation Disorders Treatment Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Indication
    • 9.2.2. By Treatment & Therapies
    • 9.2.3. By End User
    • 9.2.4. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Pigmentation Disorders Treatment Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Indication
        • 9.3.1.2.2. By Treatment & Therapies
        • 9.3.1.2.3. By End User
    • 9.3.2. Argentina Pigmentation Disorders Treatment Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Indication
        • 9.3.2.2.2. By Treatment & Therapies
        • 9.3.2.2.3. By End User
    • 9.3.3. Colombia Pigmentation Disorders Treatment Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Indication
        • 9.3.3.2.2. By Treatment & Therapies
        • 9.3.3.2.3. By End User

10. Middle East and Africa Pigmentation Disorders Treatment Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Indication
    • 10.2.2. By Treatment & Therapies
    • 10.2.3. By End User
    • 10.2.4. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Pigmentation Disorders Treatment Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Indication
        • 10.3.1.2.2. By Treatment & Therapies
        • 10.3.1.2.3. By End User
    • 10.3.2. Saudi Arabia Pigmentation Disorders Treatment Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Indication
        • 10.3.2.2.2. By Treatment & Therapies
        • 10.3.2.2.3. By End User
    • 10.3.3. UAE Pigmentation Disorders Treatment Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Indication
        • 10.3.3.2.2. By Treatment & Therapies
        • 10.3.3.2.3. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Developments
  • 12.2. Product Launches
  • 12.3. Mergers & Acquisitions

13. Global Pigmentation Disorders Treatment Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Product

15. PESTLE Analysis

16. Competitive Landscape

  • 16.1. Zerigo Health.
    • 16.1.1. Business Overview
    • 16.1.2. Company Snapshot
    • 16.1.3. Products & Services
    • 16.1.4. Financials (In case of listed companies)
    • 16.1.5. Recent Developments
    • 16.1.6. Key Personnel Details
    • 16.1.7. SWOT Analysis
  • 16.2. Bausch Health Companies Inc.
  • 16.3. Glenmark Pharmaceuticals Limited
  • 16.4. Novartis AG
  • 16.5. Pfizer Inc.
  • 16.6. Teva Pharmaceutical Industries Ltd.
  • 16.7. Bayer AG
  • 16.8. CLINUVEL PHARMACEUTICALS LTD
  • 16.9. Strides Pharma Science Limited
  • 16.10.Astellas Pharma Inc.

17. Strategic Recommendations

18. About Us & Disclaimer